Dermatologic adverse events associated with afatinib: An oral ErbB family blocker

Expert Review of Anticancer Therapy

Volumn 13, Issue 6, 2013, Pages 721-728

  Lacouture, Mario E ^a   Schadendorf, Dirk ^b   Chu, Chia Yu ^c   Uttenreuther Fischer, Martina ^d   Stammberger, Uz ^d   O'Brien, Dennis ^e   Hauschild, Axel ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

acne like rash; afatinib; dermatologic adverse event; EGF receptor; paronychia; skin rash

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AFATINIB; ALCLOMETASONE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CAPECITABINE; CLINDAMYCIN; DESONIDE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROMYCIN; FLUTICASONE PROPIONATE; GEFITINIB; LAPATINIB; METRONIDAZOLE; MINOCYCLINE; OXYTETRACYCLINE; PACLITAXEL; PLACEBO; SILVER NITRATE; STEROID; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG;

ACNE; ALOPECIA; BREAST CANCER; BREAST METASTASIS; BULLOUS DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; ERYTHRODERMA; HAIR; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTRICHOSIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MACULAR RASH; MACULOPAPULAR RASH; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PAIN; PAPULAR RASH; PAPULOPUSTULAR RASH; PARONYCHIA; PATIENT EDUCATION; PRURITUS; PUSTULE; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RADIATION DERMATITIS; REVIEW; SECONDARY INFECTION; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; SKIN FISSURE; SOLID TUMOR; VESICULAR RASH; XEROSIS;

ADMINISTRATION, ORAL; ALOPECIA; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EXANTHEMA; HUMANS; PARONYCHIA; PROTEIN KINASE INHIBITORS; PRURITUS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84879347673     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.30     Document Type: Review

References (35)

1. Iivanainen E, Elenius K. ErbB targeted drugs and angiogenesis. Curr. Vasc. Pharmacol. 8(3), 421-431 (2010).
2. Xu Y, Liu H, Chen J, Zhou Q. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol. Ther. 9(8), 572-582 (2010).
3. Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptorspecific tyrosine kinase inhibitors. Int. J. Clin. Exp. Pathol. 4(4), 403-409 (2011).
4. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
5. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342-350 (2012).
6. Lam KC, Mok TS. Targeted therapy: an evolving world of lung cancer. Respirology 16(1), 13-21 (2011).
7. Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin. Transl. Oncol. 13(10), 710-714 (2011).
8. Lacouture ME, West DP, Tigue CC, Knox K, Bennett CL. Cutaneous toxicities of targeted cancer therapies. Community Oncol. 5(7), 413-414 (2008).
9. Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities. Support. Care Cancer 19(8), 1079-1095 (2011).
10. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br. J. Dermatol. 155(4), 852-854 (2006). (Pubitemid 44352579)
11. Osio A, Mateus C, Soria JC et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br. J. Dermatol. 161(3), 515-521 (2009).
12. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res. Treat. 114(3), 485-493 (2009).
13. Eskens FA, Mom CH, Planting AS et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98(1), 80-85 (2008).
14. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
15. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538 (2012).
16. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol. 13, 539-548 (2012).
17. Lin NU, Winer EP, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133(3), 1057-1065 (2012).
18. Seiwert TY, Fayette J, Cupissol D et al. A randomized, open-label, Phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck-final data. Presented at: the Multidisciplinary Head and Neck Cancer Symposium. Phoenix, AZ, USA, 26-28 January 2012.
19. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother. Pharmacol. 69, 891-899 (2012).
20. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5), 610-621 (2007). (Pubitemid 350012125)
21. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6(10), 803-812 (2006). (Pubitemid 44450468)
22. Pomerantz RG, Mirvish ED, Geskin LJ. Cutaneous reactions to epidermal growth factor receptor inhibitors. J. Drugs Dermatol. 9(10), 1229-1234 (2010).
23. Lu PH, Kuo TC, Chang KC, Chang CH, Chu CY. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway. Br. J. Dermatol. 164(1), 38-46 (2011).
24. O'Keeffe P, Parrilli M, Lacouture M. Toxicity of targeted therapy: focus on rash and other dermatologic side effects. Oncol. Nurs. Ed. 20, 1-6 (2006).
25. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72(3-4), 152-159 (2007). (Pubitemid 351161602)
26. Witherspoon J, Wagner L, Rademaker A, West DP, Rosenbaum SE, Lacouture ME. Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor induced rash. J. Clin. Oncol. 26(Suppl. 15S), Abstract 9559 (2008).
27. Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 116(16), 3916-3923 (2010).
28. Rudin CM, Liu W, Desai A et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26(7), 1119-1127 (2008).
29. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 45(10), e155-160 (2009).
30. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25(15), 1960-1966 (2007). (Pubitemid 46972777)
31. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23(22), 5235-5246 (2005). (Pubitemid 46224035)
32. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22(15), 3003-3015 (2004). (Pubitemid 41103711)
33. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004). (Pubitemid 41079832)
34. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 21(14), 1696-1706 (2007).
35. Abraham T, Rademaker A, Ortiz S et al. Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. J. Clin. Oncol. 26(Suppl.), Abstract 19094 (2008).